trending Market Intelligence /marketintelligence/en/news-insights/trending/cgvmpf4m-gqqxvvnzsmopa2 content esgSubNav
In This List

UK price watchdog backs Kyowa Hakko, Ultragenyx's bone disease drug

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


UK price watchdog backs Kyowa Hakko, Ultragenyx's bone disease drug

The U.K.'s National Institute for Health and Care Excellence has backed the use of Kyowa Hakko Kirin Co. Ltd.'s Crysvita within the country's National Health Service.

The reversal comes months after the price watchdog rejected the medicine stating that the results from clinical trials did not show noticeable benefit in children and teenagers. The price watchdog also raised concerns about the treatment's cost effectiveness.

Crysvita, a jointly developed product by Kyowa Kirin and Ultragenyx Pharmaceutical Inc., is intended to treat a rare inherited skeletal disorder known as X-linked hypophosphatemia in children and young people.

The disorder causes low phosphate levels in the blood, leading to soft, weak bones, which can result in life-long physical disabilities and pain.

A final guidance by the regulator is expected to be published on Oct. 24.

This treatment represents a significant improvement for a condition in which there have been no advances in management for 35 years and will be much easier to adhere to compared to current therapy options. It will result in better healing of rickets, linear growth and muscle function among affected individuals," Poonam Dharmaraj, chairperson of the British Paediatric and Adolescent Bone Group, said in a statement.

The drug is already approved in the U.S. and has a conditional approval for the same indication in the EU.